
The challenges and advancements in radiopharmaceuticals
DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important? ED: One of the central challenges in radiopharmaceutical targeted alpha therapy… Read More

